HEALTH NEWS Cancer FDA panel votes against wider use of Amgen drug An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc’s drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company’s key growth drivers. 9/11 First Responders See Cancer Rates
Read more…